Tazemetostat (EPZ-6438) is an FDA-approved EZH2 inhibitor for certain sarcomas and lymphomas; in GBM, a Phase I trial in combination with TMZ was conducted (Gounder et al., 2020). This evidence concerns the gene EZH2 and glioblastoma.